Susan Xu

Ascendis Pharma

Ascendis Pharma is applying our innovative TransCon technology platform to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients' lives. Guided by our core values of patients, science and passion, we utilize our TransCon technology platform to create new and potentially best-in-class therapies. Ascendis Pharma currently has three independent endocrinology rare disease product candidates in clinical development and we're also advancing programs in Oncology and Ophthalmology. Ascendis Pharma is headquartered in Copenhagen, Denmark, with additional offices in Heidelberg, Munich, and Berlin, Germany, Palo Alto and Redwood City, California, and Princeton, New Jersey.